| 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.12.31 | 10.00 | 10.06 | 5158.12 | | 2025.12.30 | 9.99 | 11.23 | 4014.16 | | 2025.12.29 | 10.00 | 13.08 | 50379.75 | | 2025.12.26 | -0.70 | 9.51 | -15467.60 | | 2025.12.25 | 6.50 | 11.70 | 19953.36 | | 2025.12.24 | -0.14 | 4.78 | -787.25 | | 2025.12.23 | -1.70 | 5.79 | -9065.10 | | 2025.12.22 | 0.68 | 8.88 | 7663.95 | | 2025.12.19 | -1.91 | 6.15 | -4182.76 | | 2025.12.18 | 0.39 | 8.19 | 2847.56 | （文章来源：证券时报网） 证券时报·数据宝统计，两融数据来看，该股最新（12月 ...

消息面上，大摩预期，今年中国人形机器人可出货1.4万台，未来数年将逐年翻倍增长，2034年突破百 万台。 另据每经报道，当地时间2025年12月31日，埃隆.马斯克在社交媒体上表示，其脑机接口公司Neuralink 将于2026年开始对脑机接口设备进行"大规模生产"，还将在脑机植入方式上实现创新。 1月5日电，机器人概念反复活跃，倍益康、翔宇医疗、伟思医疗、熵基科技等涨20%，五洲新春走出4 连板，斯菱智驱涨超15%，双双续创历史新高，汉威科技、蓝思科技、雷迪克、博杰股份等冲高。 | 序号 | 代码 | 名称 | 0 | 最新 | 涨幅% J | | --- | --- | --- | --- | --- | --- | | 1 | 920199 | 倍益康 | 事 | 44.96 | 29.98 | | 2 | 688626 | 翔宇医疗 | 1 | 72.60 | 20.00 | | 3 | 688580 | 伟思医疗 | | 58.08 | 20.00 | | 4 | 301330 | 嫡基科技 | 1 | 39.66 | 20.00 | | 5 | 300753 | 爱朋医疗 | 1 | 33.30 ...

Group 1 - The market opened strong on the first trading day of 2026, with the ChiNext Index rising over 1.00% and the Shanghai Composite Index increasing by 0.45%, reaching a high of 3994.77 points during the session [1] - Sectors such as brain-computer interfaces, oil and gas, precious metals, and commercial aerospace showed significant gains, with nearly 3400 stocks in the Shanghai and Shenzhen markets rising [1] - Precious metals and gaming sectors led the gains, while the commercial aerospace concept stocks opened high, with companies like Goldwind Technology and Aerospace Science & Industry Corporation hitting the daily limit [3] Group 2 - Blue Arrow Aerospace's IPO was accepted, aiming to become the "first commercial rocket stock," with plans to raise 7.5 billion yuan for projects related to reusable rocket capacity and technology enhancement [4] - Market sentiment was reflected in stocks like Fenglong Co., which hit the daily limit for the sixth time, and other commercial aerospace stocks such as Shenkong Co. and China Satellite, which opened significantly higher [7] - Other sectors like robotics and digital currency also saw varied performances, with some stocks opening lower despite the overall market strength [7]

Group 1 - The market focus stocks include Fenglong Co., which has reached a limit-up for six consecutive trading days, and Shenjian Co., a commercial aerospace concept stock, which has achieved nine limit-ups in ten days [1] - Daye Co. opened down 4.87% after six consecutive limit-ups, while China Satellite opened up 6.37% after five limit-ups in six days [1] - Luxin Venture Capital opened up 5.14% after five limit-ups in six days, and the robotics concept stock Tail Co. opened up 6.54% after five limit-ups [1] Group 2 - Yuyin Co., a digital currency concept stock, opened down 5.42% after three limit-ups, while Hongying Intelligent, a liquid-cooled server concept stock, opened down 2.13% after three limit-ups [1] - The textile sector stock Zhongwang Fabric opened down 2.39% after three limit-ups in six days, and Naxing Co., an AI application stock, opened up 6.37% after two limit-ups [1]

Core Viewpoint - The Chinese cosmetics industry is projected to reach a market size of 1.1 trillion yuan, with domestic brands surpassing international brands in market share and consumer preference [1][2]. Group 1: High-Quality Development and New Productive Forces - The domestic cosmetics market retail sales are expected to reach 470 billion yuan by 2025, indicating a significant growth trajectory for the industry [2]. - New productive forces are essential for the high-quality development of the cosmetics industry, transitioning from traditional manufacturing to intelligent and lean production [4]. - New productive forces enhance production efficiency and product consistency through automation and intelligent equipment, addressing quality control challenges [4]. Group 2: Intelligent Manufacturing Practices of Domestic Brands - The past decade has seen a shift in the cosmetics manufacturing industry from experience-driven to data-driven processes, evolving through three stages: semi-automated, automated, and now data-driven intelligent stages [6]. - Leading brands like Han Shu and Pechoin have made significant investments in intelligent manufacturing, achieving production capacity increases and improved quality control [8][10]. - Domestic brands have made historical advancements in intelligent manufacturing, with automation rates rising from approximately 40% to levels comparable to international brands [10]. Group 3: R&D Innovation and Cost Management - R&D expenditure rates vary across different categories, with skincare products averaging 1.5%-5% and medical beauty products at 2%-5%, reflecting a focus on compliance and clinical data [21][23]. - Domestic brands like Han Shu and Pechoin have R&D personnel ratios comparable to international leaders, indicating strong R&D capabilities [24]. - The production cost rates for various product categories range from 15% to 30%, with domestic brands leveraging self-researched technologies and integrated supply chains to maintain competitive pricing [27][28]. Group 4: International Competitiveness of Domestic Brands - Domestic brands have achieved significant breakthroughs in the cosmetics sector, enhancing core competitiveness through new productive forces [31]. - Intelligent manufacturing has enabled micro-level quality control, establishing trust in product quality [33]. - The integration of AI and 5G technologies in manufacturing processes positions domestic brands at the forefront of global standards, driving high-quality development in the industry [33].

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

Group 1 - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, with the target company specializing in the research, production, and sales of Chemical Mechanical Polishing (CMP) equipment [1] - New Zhoubang intends to invest approximately $260 million in a lithium-ion battery materials project in Saudi Arabia, which will include a production line for 200,000 tons of carbonate solvents and 100,000 tons of ethylene glycol annually [2] - ST Keli Da is planning a change of control as its major shareholder intends to transfer 100% of its equity, leading to a potential change in company control [3] Group 2 - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with the target company focusing on high-speed copper cables for server clusters [4] - Shougang Co. expects a net profit increase of 95% to 125% for 2025, projecting a profit of between 920 million and 1.06 billion yuan, supported by product structure optimization [9] - Zai Jing Pharmaceutical has reached a global strategic cooperation agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments up to $1.075 billion [10] Group 3 - Lixun Precision plans to repurchase shares worth between 1 billion and 2 billion yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 yuan per share [12] - Tianyu Biology's actual controller is under investigation for suspected illegal stock reduction, but this will not impact the company's operations [13] - Zhongheng Electric's actual controller received a suspended prison sentence for market manipulation, but this will not adversely affect the company's operations [14]

重要内容提示： 一、股票交易异常波动的具体情况 公司股票于 2025 年 12 月 26 日、12 月 29 日、12 月 30 日连续三个交易日内 收盘价格涨幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规 定，属于股票价格异常波动。公司已于 12 月 31 日披露了《五洲新春股票交易异 证券代码：603667 证券简称：五洲新春 公告编号：2025-102 浙江五洲新春集团股份有限公司 关于股票交易风险提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 －1－ 浙江五洲新春集团股份有限公司（以下简称"公司"）股票于 2025 年 12 月 26 日、12 月 29 日、12 月 30 日连续三个交易日内收盘价格涨幅偏 离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属 于股票交易异常波动。2025 年 12 月 31 日，公司股价再次涨停，创历史 新高，鉴于公司股票价格短期涨幅较大，可能存在非理性炒作风险，公 司提醒广大投资者注意二级市场交易风险，理性决策，审慎投资。 截至 20 ...

五洲新春（维权）发布股票交易风险提示性公告称，公司股票于2025年12月26日、12月29日、12月30日 连续三个交易日内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。2025年12月31日，公司 股价再次涨停，创历史新高，鉴于公司股票价格短期涨幅较大，可能存在非理性炒作风险，公司提醒广 大投资者注意二级市场交易风险，理性决策，审慎投资。 (本文来自第一财经) ...

五洲新春发布股票交易风险提示性公告，公司股票于2025年12月26日、12月29日、12月30日连续三个交 易日内收盘价格涨幅偏离值累计超过20%，根据《上海 证券交易所交易规则》的有关规定，属于股票 交易异常波动。2025年12月31日，公司股价再次涨停，创历史新高，鉴于公司股票价格短期涨幅较大， 可能存在非理性炒作风险，公司提醒广大投资者注意二级市场交易风险，理性决策，审慎投资。截至 2025年12月31日，公司最新的TTM市盈率为279.71倍，根据万得金融终端数据显示，公司所属的证监会 行业分类"C34 通用设备制造业"，最新的TTM市盈率为60.38倍。公司TTM市盈率估值高于该行业，敬 请广大投资者注意投资风险。 ...